← 治験一覧に戻る
去勢抵抗性前立腺癌患者におけるエンザルタミドとフルタミドに関する研究
基本情報
- NCT ID
- NCT02918968
- ステータス
- 完了
- 試験のフェーズ
- 第4相
- 試験タイプ
- 介入
- 目標被験者数
- 206
- 治験依頼者名
- Astellas Pharma Inc
概要
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).
対象疾患
Prostate Cancer
介入
Enzalutamide(DRUG)
Flutamide(DRUG)
Androgen deprivation therapy(OTHER)
依頼者（Sponsor）
ファイザー株式会社(INDUSTRY)
アステラス製薬株式会社(INDUSTRY)